ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.

Yijun LuoWei LiZihang LingQinchao HuZhen Fan Bin Cheng Xiaoan Tao

Published in: Cancer medicine (2020)

ASCT2 is a significant factor for predicting overall survival in patients with OSCC, and targeting ASCT2 to inhibit glutamine metabolism may be a promising strategy for OSCC treatment.

Keyphrases

end stage renal disease
ejection fraction
induced apoptosis
newly diagnosed
prognostic factors
peritoneal dialysis
cell proliferation
cell cycle arrest
free survival
transcription factor
cancer therapy
drug delivery
combination therapy
endoplasmic reticulum stress
replacement therapy